Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis

European Journal of Surgical Oncology

Volumn 23, Issue 1, 1997, Pages 30-35

  Hardwick, R H ^a   Barham, C P ^b   Ozua, P ^b   Newcomb, P V ^a   Savage, P ^a   Powell, R ^c   Rahamin, J ^b   Alderson, D ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

^c ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

Author keywords

c erbB 2; Oesophageal carcinoma; p53; Prognosis

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

EID: 0031019074     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(97)80139-4     Document Type: Article

References (29)

1. Sagar PM, Gauperaa T, Sue LH, McMahon MJ, Johnston D. An audit of the treatment of cancer of the oesophagus. Gut 1994; 35: 941-5.
2. Streitz JJ, Andrews CJ, Ellis FJ. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993; 105: 383-7.
3. Bancewicz J. Cancer of the oesophagus: find a good surgeon. Br Med J 1990; 300: 3.
4. Coia LR, Sauter ER. Esophageal cancer. Curr Probl Cancer 1994; 18: 189-247.
5. Ferguson MK, Reeder LB, Hoffman PC, Haraf DJ, Drinkard LC, Vokes EE. Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1995; 2: 101-6.
6. Schecter AL, Stern DF, Validyanthan L, et al. The neu oncogene: an erb-B-regulated gene encoding a 185,000-Mw tumour antigen. Nature 1984; 312: 513-6.
7. Cohen JA, Weiner DB, More KF, et al. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 1989; 4: 81-8.
8. Wen D, Peles E, Cupples R, et al. Neu-differentiating factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 1992; 69: 559-72.
9. crbB2. Science 1992; 256: 1205-10.
10. Pierce JH, Arnstein P, DiMarco E, et al. Oncogenic potential of ervB-2 in human mammery epithelial cells. Oncogene 1993; 6: 1189-94.
11. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaranson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987; 237: 178-81.
12. Yokota J, Yamamoto T, Toyoshima K, et al. Amplification of c-erbB-2 oncogene in human adenocarcinoma in vivo. Lancet 1986; 1: 765-6.
13. Bargmann CI, Hung MC, Wenberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986; 45: 649-57.
14. Slamon DJ, Clark GM, Wong SG, Levin WJ, A U, McGuire WL. Human breast cancer: correlation or relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
15. Coombs LM, Pigott DA, Sweeney E, et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991; 63: 601-8.
16. Corbett I, Henry JA, Angus B, et al. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 1990; 161: 15-25.
17. Chiu KY, Loke SL, Ho FCS. Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: Comparison of cryostat and paraffin wax sections and effect of fixation. J Clin Pathol 1994; 47: 117-21.
18. Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434-8.
19. Flejou JF, Paraf F, Muzeau F, et al. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol 1994; 47: 23-6.
20. Nakamura T, Nekarda H, Hoelscher AH, et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 1994; 73: 1785-94.
21. Jain S, Filipe MI, Gullick WJ, Linehan J, Morris RW. c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer 1991; 48: 668-71.
22. Yonemura Y, Ninomiya I, Ohoyama S, et al. Expression of c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 1991; 67: 2914-8.
23. Hilton DA, West KP. c-erbB-2 oncogene product expression and prognosis in gastric carcinoma. J Clin Pathol 1992; 45: 454-6.
24. Sasano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer tells. Hum Pathol 1993; 24: 583-9.
25. Sager R. Tumour suppressor genes in the cell cycle. Curr Opin Cell Biol 1992; 4: 155-60.
26. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990; 87: 9985-61.
27. Oren M, Maltzman W, Levine AJ. Post translational regulation of the 54K cellular tumour antigen in normal and transformed cells. Mol Cell Biol 1981; 1: 101-10.
28. Kastan MB, Stone KD, Civin CI. Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. Blood 1989; 74: 1517-24.
29. Hall PA, McKee PH, Menage H, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-7.